|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2002-5-21
|
|
pubmed:abstractText |
Cellular immune responses against epitopes in conserved Gag and Pol sequences of human immunodeficiency virus type 1 have become popular targets for candidate AIDS vaccines. Recently, we used a simian-human immunodeficiency virus model (SHIV 89.6P) with macaques to demonstrate the control of a pathogenic mucosal challenge by priming with Gag-Pol-Env-expressing DNA and boosting with Gag-Pol-Env-expressing recombinant modified vaccinia virus Ankara (rMVA). Here we tested Gag-Pol DNA priming and Gag-Pol rMVA boosting to evaluate the contribution of anti-Env immune responses to viral control. The Gag-Pol vaccine raised frequencies of Gag-specific T cells similar to those raised by the Gag-Pol-Env vaccine. Following challenge, these rapidly expanded to counter the challenge infection. Despite this, the control of the SHIV 89.6P challenge was delayed and inconsistent in the Gag-Pol-vaccinated group and all of the animals underwent severe and, in most cases, sustained loss of CD4(+) cells. Interestingly, most of the CD4(+) cells that were lost in the Gag-Pol-vaccinated group were uninfected cells. We suggest that the rapid appearance of binding antibody for Env in Gag-Pol-Env-vaccinated animals helped protect uninfected CD4(+) cells from Env-induced apoptosis. Our results highlight the importance of immune responses to Env, as well as to Gag-Pol, in the control of immunodeficiency virus challenges and the protection of CD4(+) cells.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10482568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10482571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10485258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10566139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10684319,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10740236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10779808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-10957722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11039923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11309627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11333896,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11356972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11393868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11470284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11551502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-11797011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-1402655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-3422647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-7539892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-9144289,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-9151808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-9458122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12021347-9525675
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
pubmed-author:AltmanJohn DJD,
pubmed-author:AmaraRama RaoRR,
pubmed-author:EarlPatricia LPL,
pubmed-author:HerndonJames GJG,
pubmed-author:KlosIu SIuS,
pubmed-author:KozyrNatalia LNL,
pubmed-author:McClureHarold MHM,
pubmed-author:McNichollJanet MJM,
pubmed-author:MontefioriDavid CDC,
pubmed-author:MossBernardB,
pubmed-author:O'NeilShawn PSP,
pubmed-author:RobinsonHarriet LHL,
pubmed-author:SmithJames MJM,
pubmed-author:StapransSilvija ISI,
pubmed-author:VillingerFrancoisF,
pubmed-author:WyattLinda SLS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6138-46
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12021347-AIDS Vaccines,
pubmed-meshheading:12021347-Animals,
pubmed-meshheading:12021347-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12021347-Fusion Proteins, gag-pol,
pubmed-meshheading:12021347-Gene Products, env,
pubmed-meshheading:12021347-HIV,
pubmed-meshheading:12021347-HIV Antibodies,
pubmed-meshheading:12021347-HIV Infections,
pubmed-meshheading:12021347-Humans,
pubmed-meshheading:12021347-Macaca mulatta,
pubmed-meshheading:12021347-Simian Acquired Immunodeficiency Syndrome,
pubmed-meshheading:12021347-Simian immunodeficiency virus,
pubmed-meshheading:12021347-Vaccination,
pubmed-meshheading:12021347-Vaccines, DNA,
pubmed-meshheading:12021347-Vaccinia virus
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
|
|
pubmed:affiliation |
Vaccine Research Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
